You are seeing these quotes based on previous browsing related to sectors such as
| Latest | Forecast | |
|---|---|---|
| Div Yield | 3.9% | 4.3% |
| Div Cover | 2.0 | 1.9 |
| Op Mrgn | 34.2% | 40.6% |
| ROCE | 82.0% |
| Latest | Forecast | |
|---|---|---|
| P/E | 12.8 | 1,194.4 |
| PEG | 0.2 | 3.1 |
| Price / Revenue | 4.0 | 3.5 |
| Price / Book value | 3.3 |
| Latest | Forecast | |
|---|---|---|
| Revenue | -3.5% | 0.0% |
| PBT | 48.8% | n/a |
| EPS | 53.7% | 0.0% |
| DPS | 5.8% | 0.0% |
| Year Ending | Revenue ($m) |
Pre-tax ($m) |
EPS | P/E | PEG | EPS Growth | Div | Yield |
|---|---|---|---|---|---|---|---|---|
| 2016-12-31 | 52,824.00 | 8,351.00 | $1.18 | 27.5 | 6.2 | 4% | $1.20 | 3.7% |
| 2017-12-31 | 52,546.00 | 12,305.00 | $3.57 | 10.1 | 0.1 | 203% | $1.28 | 3.5% |
| 2018-12-31 | 53,647.00 | 11,885.00 | $1.90 | 22.6 | -0.5 | -47% | $1.38 | 3.2% |
| 2019-12-31 | 51,750.00 | 17,682.00 | $2.92 | 13.4 | 0.2 | 54% | $1.46 | 3.7% |
| 'Herd immunity' against Covid-19 possible in US by spring, some analysts believe Sharecast News | 25 Jan |
|---|---|
| Merck to refocus efforts on developing Covid-19 therapies Sharecast News | 25 Jan |
| Pfizer-BioNTech Covid-19 vaccine effective against new strain, fresh study shows Sharecast News | 21 Jan |